GSK-2330672 (linerixibat) is a nonabsorbable apical sodium-dependent bile acid transporter. This compound is being evaluated for treatment in patients with type 2 diabetes. In animal models of type 2 diabetes, it lowers glucose levels. GSK-2330672 also improves glucose and lipids in diabetes patients, but a high incidence of gastrointestinal adverse events (such as diarrhea) has been reported. Efficacy of GSK-2330672 in patients with primary biliary cholangitis that develop itch (pruritus) has also been examined. However, long-term used might be problematic because of the gastrointestinal adverse events.